Wockhardt Peer Comparison

NSE: WOCKPHARMA | BSE: 532300

₹1,901.10

₹-21.80 (-1.13%)

As on 30-Oct-2026IST

Market cap

₹30,814 Cr

Revenue (TTM)

₹3,564 Cr

P/E Ratio

75.3

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Market cap (₹ Cr)	30,814	32,770	31,826	26,650	22,901
Revenue (₹ Cr)	3,564	1,593	9,779	1,936	5,632
Net Profit (₹ Cr)	414.00	438.64	-270.51	288.22	662.35
Net Margin (%)	11.23	27.16	-2.71	14.79	11.75
RoE (%)	8.38	25.02	-2.55	29.77	14.34
Price to Earnings	75.34	74.62	--	92.47	34.58
Price-To-Book	6.12	17.64	3.91	19.85	4.67

Income Statement (₹ Cr)

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Operating Revenue	3,564.00	1,592.52	9,778.62	1,935.80	5,632.31
Total Income	3,686.00	1,615.23	9,993.26	1,948.58	5,638.56
Total Expenditure	2,792.00	969.32	8,578.44	1,485.56	4,354.97
EBITDA	772.00	623.20	1,200.18	450.24	1,277.34
Depreciation	226.00	41.96	887.82	50.83	306.94
EBIT	546.00	581.24	312.36	399.41	970.39
Interest	217.00	4.21	347.94	40.84	111.70
Other Income	122.00	22.71	214.64	12.78	6.25
Exceptional Items	12.00	0.00	-216.88	0.00	15.92
Profit before Tax	463.00	599.74	-37.82	371.35	880.86
Provision for Tax	49.00	161.10	232.69	83.14	218.51
Profit after Tax	414.00	438.64	-270.51	288.22	662.35

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Shareholder's Funds	4,940.00	1,857.45	8,142.24	1,288.82	5,085.00
Minority Interest	-5.00	0.51	0.55	0.00	0.00
Non-Current Liabilities	1,712.00	47.15	5,213.99	202.03	542.92
Current Liabilities	1,622.00	253.37	5,158.51	835.87	2,092.03
Total Liabilities	8,578.00	1,983.96	17,723.32	2,326.71	7,682.91

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Non-Current Assets	5,343.00	1,132.12	10,687.30	519.60	3,533.26
Current Assets	2,606.00	1,012.00	7,253.65	1,681.81	3,767.65
Total Assets	8,578.00	1,983.96	17,723.32	2,326.71	7,682.91
Total Debt*	2,125.00	26.49	5,495.48	259.37	1,338.13
Net Current Assets	984.00	758.64	2,095.14	845.94	1,675.62
Contingent Liabilities	768.26	17.25	95.72	19.09	0.93

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Cash From Operating Activities	390.00	292.17	1,652.60	205.05	793.25
Cash Flow from Investing Activities	-241.00	-265.94	-826.03	-409.72	-773.21
Cash from Financing Activities	-54.00	4.10	-38.98	283.07	379.29
Net Cash Inflow / Outflow	95.00	30.33	787.59	78.39	399.33

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
ROCE (%)	6.79	32.42	1.24	29.22	15.74
ROE (%)	8.38	25.02	-2.55	29.77	14.34
ROA (%)	4.94	22.40	-1.56	24.77	9.48
EBIT Margin (%)	15.32	36.50	3.19	20.63	17.23
Net Margin (%)	11.23	27.16	-2.71	14.79	11.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Revenue Growth (%)	18.37	45.18	9.43	46.65	24.83
EBIT Growth (%)	252.26	115.51	-3.72	62.13	40.39
Net Profit Growth (%)	377.85	95.80	-199.34	89.49	38.13
EPS Growth (%)	1,001.33	63.29	-410.28	78.60	34.88
Book Value Growth (%)	13.47	26.03	0.33	144.31	27.49

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Price / Earnings	77.32	74.62	-153.04	91.04	31.71
Price / Book Value	6.12	17.64	3.91	19.85	4.67
Dividend Yield (%)	0.00	0.06	0.00	0.09	0.21
EV/EBITDA	41.81	52.27	29.97	59.00	18.23
Market Cap (₹ Cr)	19,071.62	20,944.75	18,108.89	12,753.19	15,391.88

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Debt to Equity	0.31	0.02	0.55	0.11	0.06
Short term debt to equity ratio	0.09	0.00	0.09	0.05	0.20
Current Ratio	1.61	3.99	1.41	2.01	1.80
Quick Ratio	1.06	2.89	0.77	1.14	1.00
Interest Coverage	3.13	143.52	0.89	10.09	8.89

	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research	Granules India
Debtors to sales (%)	16.50	22.50	23.05	26.28	16.15
Asset Turnover	0.43	0.81	0.56	1.66	0.81
Receivable days	58.75	88.98	78.20	40.13	33.72
Inventory Days	75.82	56.04	93.30	60.29	54.92
Payable days	186.21	99.95	226.14	232.47	136.11
Cash Conversion Cycle	-51.64	45.07	-54.64	-132.04	-47.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.